Skip to main content
. 2021 Jul 14;13(7):488. doi: 10.3390/toxins13070488

Table 5.

Summary of adverse events across the pooled population.

Pooled Population (n = 92)
Events, n Patients, n (%)
Any adverse event 30 22 (23.9)
Serious adverse event 0 0
Severe adverse event 0 0
Adverse events by treatment received
OnabotulinumtoxinA 15 12 (13.0)
IncobotulinumtoxinA 15 13 (14.1)
Adverse events by underlying condition
Cervical dystonia (n = 58) 17 12 (20.7)
Blepharospasm (n = 34) 13 10 (29.4)